PLSE
Pulse Biosciences, Inc.
There isn't enough reported data to score PLSE yet.
PLSE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
PLSE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
PLSE PE Valuation
PLSE has no meaningful PE right now: it lost money over the past year.
PLSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PLSE's losses to grow, with revenue growing. However, they disagree widely on these estimates.
PLSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.21 | -$0.06 |
| Q2 2026 | -$1.18 | -$0.11 |
| Q1 2026 | -$1.10 | -$0.11 |
| Q4 2025 | -$1.08 | -$0.16 |
| Q3 2025 | -$1.15 | -$0.31 |
| Q2 2025 | -$1.07 | -$0.25 |
| Q1 2025 | -$0.99 | -$0.15 |
| Q4 2024 | -$0.92 | $0.00 |
PLSE is still losing money, but less than at its worst: $1.21 per share over the past year, against $2.35 at its worst in early 2020.
PLSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $395K | +359% |
PLSE's revenue is recovering but still below its 2021 peak: $395,000 last quarter, up 359% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6150% | +17533 points |
| Q2 2026 | -5823% | N/A |
| Q1 2026 | -4776% | N/A |
| Q4 2025 | -6914% | N/A |
| Q3 2025 | -23683% | N/A |
| Q2 2022 | -5288% | N/A |
| Q1 2022 | -3890% | N/A |
| Q4 2021 | -1826% | N/A |
PLSE's operating margin was −6150% last quarter, up 17533 points from the same quarter a year ago.
PLSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.4M | -$2.3M |
| Q2 2026 | -$18.8M | -$5.9M |
| Q1 2026 | -$14.6M | -$1.1M |
| Q4 2025 | -$14.9M | -$5.7M |
| Q3 2025 | -$13.1M | -$4M |
| Q2 2025 | -$12.9M | -$4.5M |
| Q1 2025 | -$13.6M | -$3.8M |
| Q4 2024 | -$9.2M | -$2.4M |
PLSE has burned cash in almost every quarter: −$64M over the past year, against −$49M the year before.
PLSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +2.7M shares |
| 1 year | +6.7% | +4.5M shares |
| 3 years | +31% | +17M shares |
| 5 years | +143% | +42.3M shares |
| Available history | +246% | +51.1M shares |
PLSE has 72M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
PLSE Net Leverage
PLSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PLSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.4 | Neutral |
| Stochastic | 72.2 | Neutral |
PLSE's weekly RSI is 62 (neutral) and its Stochastic is 72 (neutral).
PLSE PE vs Healthcare Sector
PLSE has no meaningful PE right now: it lost money over the past year.
PLSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $51.1 | 2.3% above |
| 20 week MA | $45.2 | 16% above |
| 50 week MA | $30.1 | 74% above |
| 100 week MA | $23.5 | 122% above |
| 200 week MA | $16.5 | 217% above |
PLSE is in an uptrend: it's above all five of its weekly moving averages, and 217% above its 200-week average.
PLSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.7 | $21.1 | +55% |
| 2021 | $21.1 | $15.5 | -27% |
| 2022 | $15.5 | $2.53 | -84% |
| 2023 | $2.53 | $12.2 | +384% |
| 2024 | $12.2 | $18.0 | +47% |
| 2025 | $18.0 | $14.4 | -20% |
| 2026 YTD | $14.4 | $52.3 | +263% |
PLSE's yearly returns have swung widely, from +384% in 2023 to −84% in 2022. It's up 263% so far in 2026.